Massimo Breccia | Ricerc@Sapienza

Pubblicazioni

Titolo	Pubblicato in	Anno
EFFICACY AND SAFETY OF FIRST-LINE TREATMENT WITH NILOTINIB IN ELDERLY CHRONIC MYELOID LEUKEMIA PATIENTS	HAEMATOLOGICA	2016
The 'Next-in-Cml' Study: A Prospective Multicenter Study of Deep Sequencing of the BCR-ABL1 Kinase Domain in Philadelphia Chromosome-Positive Patients with Non-Optimal Responses to Tyrosine Kinase Inhibitor Therapy	BLOOD	2016
Prognostic Value of BCR-ABL1 Transcript Type in Chronic Myeloid Leukemia Patients Treated Frontline with Nilotinib	BLOOD	2016
Inclusion of Patient's Self-Reported Fatigue into a Standard Laboratory Risk Classification Enhances Survival Prediction in Patients with Advanced Myelodysplastic Syndromes	BLOOD	2016
SAFETY AND EFFICACY OF RUXOLITINIB IN CLINICAL PRACTICE FOR PRIMARY AND SECONDARY MYELOFIBROSIS	HAEMATOLOGICA	2016
THE EUTOS LONG-TERM SURVIVAL SCORE IS PREDICTIVE FOR RESPONSE AND OUTCOME IN CML PATIENTS TREATED FRONTLINE WITH NILOTINIB-BASED REGIMENS	HAEMATOLOGICA	2016
Health-related quality of life outcomes in chronic myeloid leukemia patients treated with second generation tyrosine kinase inhibitors: do we know enough?	CURRENT MEDICAL RESEARCH AND OPINION	2016
Dasatinib first-line: Multicentric Italian experience outside clinical trials	LEUKEMIA RESEARCH	2016
MEANING OF MOLECULAR RESPONSES FLUCTUATION IN CHRONIC MYELOID LEUKEMIA PATIENTS TREATED WITH LONG-TERM IMATINIB	HAEMATOLOGICA	2016
2013 EUROPEAN LEUKEMIANET RESPONSE CRITERIA VALIDATION IN CHRONIC MYELOID LEUKEMIA PATIENTS TREATED FRONTLINE WITH 3 AVAILABLE TKIS OUTSIDE CLINICAL TRIALS	HAEMATOLOGICA	2016
Impact of Age on Efficacy, Safety, and Long-Term Outcome of Chronic Myeloid Leukemia (CML) Patients Treated in First-Line with Nilotinib: An Analysis of the Gimema CML Working Party	BLOOD	2016
Current standard treatment of adult acute promyelocytic leukaemia	BRITISH JOURNAL OF HAEMATOLOGY	2016
Proposal for a tailored stratification at baseline and monitoring of cardiovascular effects during follow-up in chronic phase chronic myeloid leukemia patients treated with nilotinib frontline	CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY	2016
How has treatment changed for blast phase chronic myeloid leukemia patients in the tyrosine kinase inhibitor era? A review of efficacy and safety	EXPERT OPINION ON PHARMACOTHERAPY	2016
An increase in hemoglobin, platelets and white blood cells levels by iron chelation as single treatment in multitransfused patients with myelodysplastic syndromes: clinical evidences and possible biological mechanisms	ANNALS OF HEMATOLOGY	2015
Deferasirox chelation therapy in patients with transfusion-dependent MDS: a real-world report from two regional Italian registries: Gruppo Romano Mielodisplasie and Registro Basilicata.	EUROPEAN JOURNAL OF HAEMATOLOGY	2015
Characteristics and outcome of therapy-related myeloid neoplasms. report from the Italian network on secondary leukemias	AMERICAN JOURNAL OF HEMATOLOGY	2015
Catheter-associated bloodstream infections and thrombotic risk in hematologic patients with peripherally inserted central catheters (PICC).	SUPPORTIVE CARE IN CANCER	2015
Are ET and PV Patients Two Similar Populations As Concern Thrombotic Risk Factors?	BLOOD	2015
Application of the International Prognostic Score of Thrombosis for Essential Thrombocytemia(ET) (IPSET-Thrombosis) in a Cohort of ET Patients: Experience from Gruppo Laziale for Myeloproliferative Ph Negative Neoplasms	BLOOD	2015